Characteristic | Whole SSc Population, n = 7286 | Patients with Diffuse Cutaneous Subtype, n = 2393 | Patients with Limited Cutaneous Subtype, n = 4210 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
With TFR, n = 802 | Without TFR, n = 6484 | p | Stepwise Regression, OR (95% CI) | With TFR, n = 486 | Without TFR, n = 1907 | p | Stepwise Regression, OR (95% CI) | With TFR, n = 260 | Without TFR, n = 3950 | p | Stepwise Regression OR (95% CI) | |
Age, mean ± SD, yrs | 56 ± 15 | 58 ± 18 | 0.001* | NS | 51 ± 13 | 55 ± 15 | 0.002* | 0.69 (0.48–0.85) | 59 ± 15 | 60 ± 19 | 0.3 | NS |
Females (%) | 666 (83) | 5600 (86) | 0.001* | NS | 376 (77) | 1517 (80) | 0.3 | NS | 236 (91) | 3555 (90) | 0.8 | NS |
Disease duration, mean ± SD, yrs | 9 ± 10 | 10 ± 11 | 0.53 | NS | 4 ± 8 | 9 ± 10 | 0.0001* | 0.56 (0.32–0.83) | 10 ± 11 | 10 ± 12 | 0.9 | NS |
Synovitis, n (%) | 291 (36) | 900 (14) | < 0.0001* | 2.31 (1.91–2.79) | 173 (36) | 311 (16) | < 0.0001* | 2.20 (1.69–2.87) | 93 (36) | 477 (12) | < 0.0001* | 2.90 (2.18–3.96) |
Joint contracture, n (%) | 528 (66) | 1736 (27) | < 0.0001* | 3.04 (2.54–3.65) | 365 (75) | 802 (42) | < 0.0001* | 3.15 (2.44–4.06) | 139 (53) | 836 (21) | < 0.0001* | 2.66 (2.01–3.54) |
Raynaud phenomenon, n (%) | 765 (95) | 6181 (95) | 0.93 | NS | 467 (96) | 1821 (95) | 0.7 | NS | 250 (96) | 3789 (96) | 0.9 | NS |
Digital ulceration, n (%) | 383 (48) | 1908 (29) | < 0.0001* | 1.21 (1.01–1.44) | 260 (53) | 722 (38) | < 0.0001* | 1.25 (1.02–1.78) | 107 (41) | 1088 (28) | < 0.0001* | 1.38 (1.03–1.83) |
Muscle weakness, n (%) | 367 (46) | 1583 (24) | < 0.0001* | 1.42 (1.18–1.70) | 245 (50) | 625 (33) | < 0.0001* | 1.32 (1.03–2.14) | 103 (40) | 801 (20) | < 0.0001* | 1.84 (1.38–2.46) |
Pulmonary fibrosis, n (%) | 399 (50) | 2208 (34) | < 0.0001* | 1.22 (1.02–1.46) | 278 (57) | 939 (49) | 0.003* | NS | 106 (41) | 1110 (28) | < 0.0001* | 1.49 (1.12–1.98) |
Elevated sPAP, n (%) | 272 (34) | 1484 (23) | < 0.0001* | NS | 175 (36) | 463 (24) | < 0.0001* | NS | 78 (30) | 874 (22) | 0.02* | NS |
Renal crisis, n (%) | 36 (4) | 124 (2) | < 0.0001* | NS | 27 (6) | 74 (4) | 0.1* | NS | 7 (3) | 42 (1) | 0.03* | NS |
Positive ANA, n (%) | 740 (92) | 5877 (91) | 0.78 | NS | 444 (91) | 1727 (91) | 0.4 | NS | 234 (90) | 3629 (92) | 0.6 | NS |
Positive antitopoisomerease-1 antibodies, n (%) | 382 (48) | 1911 (29) | < 0.0001* | NS | 291 (60) | 1026 (54) | 0.001* | NS | 95 (37) | 763 (19) | 0.0001* | 1.32 (1.15–1.72) |
Positive anticentromere antibodies, n (%) | 130 (16) | 2266 (35) | < 0.0001* | NS | 21 (4) | 119 (6) | 0.2 | NS | 101 (39) | 1950 (49) | 0.001* | NS |
Elevated CPK, n (%) | 115 (14) | 466 (7) | 0.005* | NS | 80 (16) | 214 (11) | 0.001* | NS | 21 (8) | 183 (5) | 0.002* | NS |
Elevation of acute-phase reactants, n (%) | 377 (47) | 1776 (27) | < 0.0001* | NS | 267 (55) | 696 (36) | < 0.0001* | NS | 95 (37) | 923 (23) | < 0.0001* | NS |
Proteinuria, n (%) | 92 (11) | 343 (5) | < 0.0001* | 1.38 (1.02–1.87) | 64 (13) | 149 (8) | 0.0002* | 1.22 (1.01–1.79) | 17 (7) | 155 (4) | 0.05* | NS |
TFR: tendon friction rubs; NS: not significant; CPK: creatine phosphokinase; ANA: antinuclear antibodies; SSc: systemic sclerosis; sPAP: systolic pulmonary artery pressure.
↵* Variables included for the multivariate stepwise logistic regression analysis.